254 related articles for article (PubMed ID: 24389984)
1. The association between BRAF (V600E) mutation and pathological features in PTC.
Liu X; Yan K; Lin X; Zhao L; An W; Wang C; Liu X
Eur Arch Otorhinolaryngol; 2014 Nov; 271(11):3041-52. PubMed ID: 24389984
[TBL] [Abstract][Full Text] [Related]
2. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma.
Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY
Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894
[TBL] [Abstract][Full Text] [Related]
4. [Association of BRAF(V) 600E mutation with clinical pathological features in papillary thyroid carcinoma: meta-analysis].
Yan K; Lin X; Li S; Bao H; Zhao L; Liu X
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep; 49(9):759-64. PubMed ID: 25487587
[TBL] [Abstract][Full Text] [Related]
5. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.
Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D
Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322
[TBL] [Abstract][Full Text] [Related]
6. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
[TBL] [Abstract][Full Text] [Related]
7. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
[TBL] [Abstract][Full Text] [Related]
8. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
9. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Liu C; Chen T; Liu Z
World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
11. Risk and Prognostic Factors for BRAF
Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J
Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194
[TBL] [Abstract][Full Text] [Related]
12. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
14. Effects of Coexistent BRAF
Moon S; Song YS; Kim YA; Lim JA; Cho SW; Moon JH; Hahn S; Park DJ; Park YJ
Thyroid; 2017 May; 27(5):651-660. PubMed ID: 28181854
[TBL] [Abstract][Full Text] [Related]
15. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
[TBL] [Abstract][Full Text] [Related]
16. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
17. The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas.
Kurt B; Yalçın S; Alagöz E; Karslıoğlu Y; Yigit N; Günal A; Deveci MS
Endocr Pathol; 2012 Sep; 23(3):135-40. PubMed ID: 22767446
[TBL] [Abstract][Full Text] [Related]
18. The synergic effect of BRAF
Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
[TBL] [Abstract][Full Text] [Related]
19. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
